التفاصيل البيبلوغرافية
| العنوان: |
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. |
| المؤلفون: |
Carlsen, Lindsey1,2,3,4,5 (AUTHOR) lindsey_carlsen@brown.edu, Huntington, Kelsey E.1,2,3,4,5 (AUTHOR) kelsey_huntington@brown.edu, El-Deiry, Wafik S.1,2,3,4,5,6 (AUTHOR) wafik@brown.edu |
| المصدر: |
Cancers. Feb2022, Vol. 14 Issue 4, p1028. 1p. |
| مصطلحات موضوعية: |
*THERAPEUTIC use of monoclonal antibodies, *BIOMARKERS, *CYTOKINES, *IMMUNE checkpoint inhibitors, *COLORECTAL cancer, *IMMUNOTHERAPY, *ONCOLYTIC virotherapy, *THERAPEUTICS |
| مستخلص: |
Simple Summary: Late-stage colorectal cancer treatment often involves chemotherapy and radiation that can cause dose-limiting toxicity, and therefore there is great interest in developing targeted therapies for this disease. Immunotherapy is a targeted therapy that uses peptides, cells, antibodies, viruses, or small molecules to engage or train the immune system to kill cancer. Here, we discuss the preclinical and clinical development of immunotherapy for treatment of colorectal cancer and provide an overview of predictive biomarkers for such treatments. We also consider open questions including optimal combination treatments and sensitization of colorectal cancer patients with proficient mismatch repair enzymes. Though early-stage colorectal cancer has a high 5 year survival rate of 65–92% depending on the specific stage, this probability drops to 13% after the cancer metastasizes. Frontline treatments for colorectal cancer such as chemotherapy and radiation often produce dose-limiting toxicities in patients and acquired resistance in cancer cells. Additional targeted treatments are needed to improve patient outcomes and quality of life. Immunotherapy involves treatment with peptides, cells, antibodies, viruses, or small molecules to engage or train the immune system to kill cancer cells. Preclinical and clinical investigations of immunotherapy for treatment of colorectal cancer including immune checkpoint blockade, adoptive cell therapy, monoclonal antibodies, oncolytic viruses, anti-cancer vaccines, and immune system modulators have been promising, but demonstrate limitations for patients with proficient mismatch repair enzymes. In this review, we discuss preclinical and clinical studies investigating immunotherapy for treatment of colorectal cancer and predictive biomarkers for response to these treatments. We also consider open questions including optimal combination treatments to maximize efficacy, minimize toxicity, and prevent acquired resistance and approaches to sensitize mismatch repair-proficient patients to immunotherapy. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder